Propanc Biopharma, Inc. (PPCB) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$0.32

From 52W high−99.23%

Volume187646.00

Market cap$722243.61

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$0.32

From 52W high

−99.23%

Volume

187646.00

Market cap

$722243.61

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.0x

P/E (TTM)

—

RSI (14)

25.1

MomentumView details →

1D Return

−7.31%

YTD Return

−97.68%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.0x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−200.63%

ROA (TTM)

−147.60%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+96.00%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+95.25%

EBITDA YoY

+70.31%

MomentumView details →

1D Return

−7.31%

YTD Return

−97.68%

1Y Return

−99.24%

RSI (14)

25.1

vs 50D SMA

−62.79%

vs 200D SMA

−89.19%

Capital & dividendView details →

Debt/Equity

0.05x

Current Ratio

2.55x

Quick Ratio

2.55x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.38

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−18.86M

Op. CF (TTM)

−5.79M

Latest newsMore news →

Propanc Biopharma announced new preclinical research identifying its pancreatic proenzyme formulation PRP as a potential strategy for addressing chemotherapy resistance in pancreatic cancer.4d ago

Propanc Biopharma announced publication of a peer-reviewed pilot study evaluating its PRP pancreatic proenzyme formulation in pancreatic and ovarian cancer.6d ago

Similar companies

Voyager Acquisition CorpVRXAW IO Biotech, Inc.IOBT SciSparc Ltd.SPRC NKGen Biotech, Inc. WarrantsNKGNW BNB Plus Corp.BNBX Curis, Inc.CRIS Find similar companies →

Latest newsMore news →

Propanc Biopharma announced new preclinical research identifying its pancreatic proenzyme formulation PRP as a potential strategy for addressing chemotherapy resistance in pancreatic cancer.4d ago Propanc Biopharma announced publication of a peer-reviewed pilot study evaluating its PRP pancreatic proenzyme formulation in pancreatic and ovarian cancer.6d ago Propanc Biopharma announced plans to commence a world-first Phase 1b first-in-human study of its drug candidate PRP in February 2027.41d ago